| General Information of Drug Metabolite (DM) (ID: DM017119) |
| DM Name |
GDC-0199 metabolite M27
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Oxidation - Oxidation |
GDC-0199
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| GDC-0199 |
DR5340
|
Approved |
Solid tumour/cancer |
|
|
| References |
| 1 |
Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
